Bausch Health Companies

Bausch Health, through its aesthetics division Solta Medical, is introducing the Fraxel FTX laser system in Australia. The upgraded system uses two wavelengths (1927 nm for the epidermis, 1550 nm for the dermis), creates microscopic treatment zones and targets indications such as fine lines, wrinkles, acne scars, pigment lesions, as well as actinic keratosis and melasma. Innovations include a lighter handpiece, integrated cooling, AccuTRAC tracking and a modernized user interface; the device is prescription-only and will be supported by Solta Medical with clinical and hands-on training. » More on de.investing.com

Bausch Health shares closed at $4.56, marking a 52-week low and a one-year performance of -28.42%. Analysts nevertheless see upside and cite price targets between $6 and $9, while data from InvestingPro classify the stock as undervalued. Investors are watching the quarterly report due in eight days, seen as a potential turning point for the $1.75 billion pharmaceutical group. » More on de.investing.com

Bausch Health Canada secured listing of PrOKEDI 75mg and 100mg dosages in the Régie de l'assurance maladie du Québec formulary, marking a key reimbursement milestone for the injectable risperidone treatment for adults with schizophrenia. PrOKEDI provides rapid therapeutic concentrations without oral supplementation or a loading dose and offers four-week dosing. The company said it will pursue coverage in other provinces following a prior Letter of Intent from the pan-Canadian Pharmaceutical Alliance to advance public drug program access. » More on finance.yahoo.com

Bausch Health will release results for the quarter ended March 31, 2026 on April 29, 2026. The analyst consensus sees earnings per share of 0.928 CAD (prior year: -0.230 CAD) and revenue of around 3.30 billion CAD (+1.96% versus 3.24 billion CAD). For the current fiscal year analysts on average expect earnings per share of 5.99 CAD (prior year: 0.590 CAD) and revenue of about 14.62 billion CAD (prior year: 14.34 billion CAD). » More on finanzen.net

Barclays cut its price target for Bausch Health from $8 to $7 but kept an Equal Weight rating, implying roughly 37% upside. CEO Thomas Appio highlighted year-on-year growth in key metrics and cited the recently acquired full-service aesthetics distribution business in China as a driver of geographic and commercial expansion. Analyst Glen Santangelo warned of challenges from loss of exclusivity in 2028 that temper the outlook. » More on finance.yahoo.com